4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention

Lisa Maher, Gilda Tachedjian, Jennifer F Hoy, Iona Millwood, Rebecca J Guy, Nick M Walsh, John J Zaunders, Anthony Jaworowski and John M Kaldor
Med J Aust 2007; 187 (11): . || doi: 10.5694/j.1326-5377.2007.tb01441.x
Published online: 3 December 2007

The first IAS conference to highlight biomedical prevention was held in Sydney in July 2007

Over 5000 delegates from 133 countries met in Sydney in July for the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, the first major international conference on the biomedical aspects of AIDS to be held in Australia. It was also the first conference in this series to include prevention in its title and to assign a central role to prevention research in the scientific program, alongside basic science and clinical research. Coinciding with the conference was the release of the Sydney Declaration, which calls for 10% of all resources devoted to HIV programming to be dedicated to research1 (Box). The conference provided Australia with an opportunity to benefit from the presence of world-leading scientists from a number of disciplines, as well as to showcase outstanding Australian achievements in HIV research.

  • Lisa Maher1
  • Gilda Tachedjian2,3
  • Jennifer F Hoy4,5
  • Iona Millwood1
  • Rebecca J Guy2
  • Nick M Walsh4
  • John J Zaunders6
  • Anthony Jaworowski2,4
  • John M Kaldor1

  • 1 National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW.
  • 2 Macfarlane Burnet Institute for Medical Research, Melbourne, VIC.
  • 3 Department of Microbiology, Monash University, Melbourne, VIC.
  • 4 Department of Medicine, Monash University, Melbourne, VIC.
  • 5 Clinical Research Unit, Infectious Diseases, Alfred Hospital, Melbourne, VIC.
  • 6 Centre for Immunology, St Vincent’s Hospital, Sydney, NSW.


Competing interests:

Lisa Maher and John Kaldor are principal investigators on the male tolerance study of Vivagel (a candidate vaginal microbicide) mentioned in the article (abstract TUAC1LB); this was funded by a National Institutes of Health contract awarded to Starpharma. Iona Millwood is a researcher employed by the University of New South Wales, Sydney, on this study.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.